. 2018 Mar 6;9(2):e02425-17. doi: 10.1128/mBio.02425-17

TABLE 1 .

Antiviral activity of DRV against HIV-1 clones carrying various mutations in protease

Infectious clone	Amino acid substitution(s) in PR	IC₅₀ (mean ± SD) (nM) (fold change)^a
Infectious clone	Amino acid substitution(s) in PR	DRV	APV^b	AZT^c	RAL^d
rHIV^WT	None	3.1 ± 0.3	24 ± 2	30 ± 9	4.9 ± 3.2
rHIV_DRV^R_P51^I32V	L10I, I15V, K20R, L24I, L33F, M36I, M46L, I54M, L63P, K70Q, V82I, I84V, L89M	29 ± 8 (9)	ND	ND	ND
rHIV_DRV^R_P51^F33L	L10I, I15V, K20R, L24I, V32I, M36I, M46L, I54M, L63P, K70Q, V82I, I84V, L89M	120 ± 33 (38)	ND	ND	ND
rHIV_DRV^R_P51^M54I	L10I, I15V, K20R, L24I, V32I, L33F, M36I, M46L, L63P, K70Q, V82I, I84V, L89M	43 ± 15 (14)	ND	ND	ND
rHIV_DRV^R_P51^V84I	L10I, I15V, K20R, L24I, V32I, L33F, M36I, M46L, I54M, L63P, K70Q, V82I, L89M	28 ± 6 (9)	ND	ND	ND
rHIV_DRV^R_P51	L10I, I15V, K20R, L24I, V32I, L33F, M36I, M46L, I54M, L63P, K70Q, V82I, I84V, L89M	330 ± 10 (106)	ND	ND	ND
rHIV^{V32I/L33F/I54M/I84V}	V32I, L33F, I54M, I84V	639 ± 17 (205)	ND	ND	ND
rHIV^V32I	V32I	0.2 ± 0.05 (0.06)	31 ± 3 (1.3)	32 ± 6 (1.1)	4.7 ± 0.5 (1.0)
rHIV^L33F	L33F	3.2 ± 0.1 (1.0)	35 ± 2 (1.3)	45 ± 12 (1.5)	5.6 ± 1.1 (1.1)
rHIV^I54M	I54M	2.7 ± 0.1 (0.9)	324 ± 86 (13)	34 ± 17 (1.1)	5.1 ± 2.2 (1.0)
rHIV^I84V	I84V	3.3 ± 0.3 (1.1)	313 ± 98 (13)	44 ± 18 (1.5)	6.4 ± 6.0 (1.3)

Data shown represent mean IC₅₀ values (±1 standard deviation) derived from the results of three independent experiments conducted in triplicate. The IC₅₀s were determined by employing MT-4 cells exposed to each infectious HIV-1 clone (50 TCID₅₀s) in the presence of each inhibitor and using the inhibition of p24 Gag protein production as an end point. The fold change values in parentheses were calculated by dividing IC₅₀s against each virus by the IC₅₀ against rHIV^WT. ND, not determined.

APV, amprenavir, a protease inhibitor.

AZT, zidovudine, a nucleoside reverse transcriptase inhibitor.

RAL, raltegravir, an integrase strand transfer inhibitor.